«« | Feb 2008 | »» | ||||
S | M | T | W | T | F | S |
1
|
2
|
|||||
3 |
4
|
5
|
6 |
7
|
8
|
9 |
10 |
11
|
12
|
13
|
14
|
15
|
16
|
17 |
18
|
19
|
20
|
21
|
22
|
23
|
24
|
25 |
26
|
27 | 28 | 29 |
Reuters:
Antidepressants effective treatment options for OCD
Fox News:
Hopelessness often lingers after depression lifts
KOCO-5, Oklahoma City:
Under their strategic alliance with NeuroSearch, GlaxoSmithKline (GSK) has initiated Phase II clinical development of drug candidate NS2359 (GSK372475) in patients diagnosed with major depressive disorder. The studies will be conducted in multiple centres worldwide and will involve several hundred patients.
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile which enhances the function of the three neurotransmitters serotonin, noradrenalin and dopamine.
This "triple-mode-of-action" of action is expected to produce a reduction in all disease symptoms and the possibility of an earlier onset of action compared to current antidepressants. A previous clinical study in adults with attention deficit hyperactivity disorder has shown that NS2359 induces a significant improvement of cognitive function.
tags: clinical depression major depressive disorder
links: digg this del.icio.us technorati reddit